STAT+: Lilly’s Jaypirca approved as first-line CLL therapy

Written and edited by the WorldPing NewsdeskPublished Updated Original reporting: STAT
STAT+: Lilly’s Jaypirca approved as first-line CLL therapyWorldPing
Image via STAT.

What happened

Eli Lilly’s Jaypirca has won FDA approval for previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.

Key facts

  • Reported by STAT and published Mon, 05 Oct 2026 13:55:41 UTC.

Why it matters

Outbreaks, approvals and guidance changes have direct practical consequences for care, travel and public-health planning.

What to watch next

  • Case numbers and official guidance updates
  • Regulatory decisions in other countries
  • Supply, recall or access changes

Sources

The original report was published by STAT. WorldPing does not claim that reporting — this page summarises and contextualises it.

Read the full report at STAT

Related WorldPing coverage